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ABSTRACT
Voltage-gated Na+ channels (VGSCs) mediate action potential firing and regulate 
adhesion and migration in excitable cells. VGSCs are also expressed in cancer cells. 
In metastatic breast cancer (BCa) cells, the Na
v
1.5 α subunit potentiates migration 
and invasion. In addition, the VGSC-inhibiting antiepileptic drug phenytoin inhibits 
tumor growth and metastasis. However, the functional activity of Na
v
1.5 and its 
specific contribution to tumor progression in vivo has not been delineated. Here, we 
found that Na
v
1.5 is up-regulated at the protein level in BCa compared with matched 
normal breast tissue. Na+ current, reversibly blocked by tetrodotoxin, was retained 
in cancer cells in tumor tissue slices, thus directly confirming functional VGSC activity 
in vivo. Stable down-regulation of Na
v
1.5 expression significantly reduced tumor 
growth, local invasion into surrounding tissue, and metastasis to liver, lungs and 
spleen in an orthotopic BCa model. Na
v
1.5 down-regulation had no effect on cell 
proliferation or angiogenesis within the in tumors, but increased apoptosis. In vitro, 
Na
v
1.5 down-regulation altered cell morphology and reduced CD44 expression, 
suggesting that VGSC activity may regulate cellular invasion via the CD44-src-cortactin 
signaling axis. We conclude that Na
v
1.5 is functionally active in cancer cells in breast 
tumors, enhancing growth and metastatic dissemination. These findings support the 
notion that compounds targeting Na
v
1.5 may be useful for reducing metastasis.
INTRODUCTION
Metastasis is the main cause of morbidity and 
mortality from solid tumors, including breast cancers (BCa) 
[1, 2]. Thus, there is a an urgent need to better understand 
the mechanism(s) involved in metastasis in order to identify, 
characterize and validate new molecular targets [3].
Various classes of ion channels, including voltage-
gated Na+ channels (VGSCs), play major roles in cancer 
progression [4, 5]. VGSCs are heteromeric protein 





1.9) and smaller, non-pore-forming β subunits (β1-
β4), which are also cell adhesion molecules (CAMs) [6]. 
VGSCs are classically responsible for the influx of Na+ 
underlying the action potential in electrically excitable 
cells. VGSCs are therefore well-established clinical targets 
for the treatment of a range of neurological disorders [7]. 
VGSC α and β subunits play a critical role during central 
nervous system (CNS) development, regulating electrical 
excitability, proliferation, fasciculation, neurite outgrowth, 
pathfinding and migration [8]. In addition, the Na
v
1.5 α 
subunit (gene, SCN5A) is highly expressed in the heart, 
where it underlies the cardiac action potential, is required 
for normal heart development, and is the target of a 
number of antiarrhythmic drugs [9–11]. Thus, regulation 
of tissue and organ development may be a general feature 
of VGSCs, both in the CNS and the heart. Emerging 
evidence suggests that VGSCs are also widely expressed 
in cells traditionally considered to be non-excitable, 
including astrocytes, fibroblasts, immune cells, microglia 
and cancer cells [12].
Na
v
1.5 is expressed in metastatic triple-negative 
(lacking estrogen receptor, progesterone receptor, and 
HER2) MDA-MB-231 cells, where it enhances migration 
and invasion through an extracellular matrix in vitro [13, 
14]. Similar findings in cells from other cancer types 
suggest that VGSC activity may be a general feature of 
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tumors [4, 15]. SCN5A mRNA is up-regulated in breast 
tumors compared to normal breast tissue, and associates 
with recurrence, metastasis and reduced survival [14, 16]. 
Interestingly, in BCa cells, Na
v
1.5 is predominantly 
expressed in its neonatal D1:S3 splice form, and it is this 
splice variant that is responsible for VGSC-dependent 
invasion [14, 17]. Na+ current carried by Na
v
1.5 potentiates 
invasion via regulation of the Na+/H+ exchanger, NHE1, 
resulting in local extracellular acidification and activation 
of pH-dependent cysteine cathepsins [18–20]. In addition, 
Na
v
1.5 is a key regulator of an invasion-promoting gene 
network in colorectal cancer cells [21]. The VGSC β1 
subunit is also up-regulated in BCa, and increases tumor 
growth and metastasis [22]. Thus, VGSC α and β subunits 
may both play a role in cancer progression. We have found 
that the VGSC-inhibiting Class Ib antiarrhythmic agent 
and antiepileptic drug phenytoin significantly reduces Na+ 
current in MDA-MB-231 cells in vitro [16], and reduces 
proliferation, tumor growth and metastasis in vivo [23]. 
However, the specific contributions of Na
v
1.5 to tumor 
growth, invasion and metastasis in vivo have not been 
previously investigated.
The purpose of the present study was to investigate 
the specific involvement of Na
v
1.5 in BCa progression 
in vivo. We show that Na
v
1.5 is up-regulated at the protein 
level in human BCa samples compared with normal 
breast tissue. In addition, using slice recording, we show 
for the first time that Na+ currents exist in tumor tissue, 
confirming that VGSCs are functionally active in acutely 
prepared ex vivo tumor tissue preparations. Furthermore, 
stable down-regulation of Na
v
1.5 using lentiviral shRNA 
significantly reduces tumor growth, local invasion and 
metastasis in vivo. We propose that Na
v
1.5 is functionally 
active in breast tumors, enhancing both tumor growth 
and metastasis. These findings suggest that Na
v
1.5 should 





1.5 is up-regulated in breast tumors
We have previously shown that SCN5A is up-
regulated at the mRNA level in breast tumors compared to 
normal, non-cancer tissue [16]. A small qualitative study 
(n = 10) revealed a similar up-regulation of expression of the 
neonatal Na
v
1.5 splice variant at the protein level [14]. Here, 
we studied the expression of Na
v
1.5 at the protein level in 
human tissue samples by immunohistochemistry (IHC), 
using an antibody that recognizes both adult and neonatal 
splice variants [21]. Na
v
1.5 was expressed in the cytoplasm 
and at the plasma membrane of normal epithelial and 
carcinoma cells (Figure 1A, 1B). Antibody specificity was 
confirmed in breast tumor tissue and rat heart tissue, where 
Na
v
1.5 is highly expressed, by absence of staining following 
pre-incubation with the immunizing peptide (Figure 1C and 
Supplementary Figure S1A–S1C). Importantly, Na
v
1.5 
expression was significantly higher in tumor than in matched 
surrounding non-cancer breast tissue (P < 0.001; Figure 
1E). Interestingly, the proportion of cases with a recorded 
lymph node metastasis was ~3-fold larger for tumors with 
high Na
v
1.5 expression, than for those with low Na
v
1.5 
expression, although this was not statistically significant (P 
= 0.19; Supplementary Table S1). The Na
v
1.5 expression 
level in the primary tumor did not correlate with age, ER 
status, grade, menopausal status, or 5-year BCa-specific 
survival (Supplementary Table S1). However, the Na
v
1.5 
expression level strongly correlated with β1 expression in 
adjacent sections from the same tumor samples (P < 0.001; 
Figure 1Biii, 1D, 1F) [22]. Western blotting across a panel 
of BCa cell lines and the non-cancer mammary epithelial 
cell line MCF-10A revealed that Na
v
1.5 is highly expressed 
in the strongly metastatic MDA-MB-231 cell line, but is 
not detected in other, less invasive BCa or normal epithelial 
cell lines (Figure 1G). This is consistent with previous 
observations indicating that the neonatal splice variant of 
Na
v
1.5 is absent from MCF-7 cells, but is present in MDA-
MB-231 cells [14]. Interestingly, in contrast to the tumor 
specimens, Na
v
1.5 expression in these cell lines does not 
match that of β1, which we showed previously to be most 
highly expressed in MCF-7 cells [22, 24]. Together, these 
data suggest that Na
v
1.5 is up-regulated in a subset of breast 
tumors at the protein level and its expression may associate 
with β1 in some tumors.
Na+ current is retained in tumors in vivo
Na+ current carried by VGSCs has been detected 
by whole-cell patch clamp recording of cultured cell lines 
from a number of different cancers [13, 14, 21, 25–29], 
providing direct evidence for functional VGSC expression 
in metastatic cancer cells in vitro. In addition, treatment 
of prostate tumor-bearing rats with tetrodotoxin (TTX) 
[30], and breast tumor-bearing mice with phenytoin [23] 
or ranolazine [31] reduces metastasis, providing indirect 
evidence for VGSC function in metastatic tumors in vivo. 
However, to date, no group has directly studied functional 
VGSC activity in tumor tissue. To address this gap, we 
next used whole-cell patch clamping to record membrane 
Na+ currents in tissue slices prepared from tumors 20–37 
days after orthotopic implantation of MDA-MB-231 
breast cancer cells (Figure 2A). We recorded from cells 
located on the upper surface of tissue slices at various 
distances from the edge of the tumor (Figure 2B). Tumor 
cells displayed fast inward Na+ currents ex vivo that 
were similar to currents detected in MDA-MB-231 cells 
in vitro (39/60 cells recorded; Figure 2C–2E) [13, 14, 16, 
17]. Importantly, TTX (30 μM) reversibly inhibited the 
Na+ currents, thus confirming these as VGSC currents 
(Figure 2F). We next compared the peak Na+ current density 
of cells at the tumor periphery (≤1 mm from the lateral 




1.5 expression in breast cancer. A. Representative images of non-cancer breast tissue and B. breast tumor tissue in 
which Na
v
1.5 was (i) absent, (ii) weakly positive, and (iii) strongly positive. C. Absence of immunoreactivity in a “strongly positive” tumor 
stained with anti-Na
v
1.5 antibody preincubated with immunizing peptide. D. Adjacent section from the same tumor in (Biii) stained with 
anti-β1 antibody [22]. Scale bar, 100 μm. Insets, higher magnification images of tumor cells, scale bar, 50 μm. E. Mean Allred score for 
matched normal breast and tumor samples. Data are mean + SEM (n = 36 matched cases). ***P < 0.001. F. Na
v
1.5 vs. β1 IHC score [22] 
in adjacent sections from matched tumor samples. Pearson r = 0.66 (P < 0.001). Solid line, linear regression; broken lines 95% confidence 
intervals. G. Western blot of Na
v
1.5 expression across a panel of BCa cell lines. Loading control = heat shock protein 90 (HSP90). Positive 




Figure 2: Functional Na+ currents are retained in tumors in vivo. A. Tumor preparation for slice recording. Recordings were 
taken from cells in (1) the periphery (≤1 mm from tumor surface, (2) the intermediate zone (>1 mm and ≤ 1.5 mm from surface), and (3) 
the center (>1.5 mm from surface). B. Representative (i) low magnification and (ii) high magnification bright field images of upper surface 
of tumor slice prepared for recording. P, location of patch pipette, *, location of recorded cell. Scale bars, 100 μm in (i) and 50 μm in (ii). 
C. Typical whole-cell recording from tumor cell in a tissue slice after depolarization to voltages in the range −60 to +30 mV in 10 mV steps 
following a 250 ms prepulse at −120 mV. D. Current-voltage relationship of Na+ currents recorded from cells in tumor slices (n = 39, pooled 
across all regions). E. Activation and steady-state inactivation of Na+ currents recorded from cells in tumor slices. Normalized conductance 
(G/G
max
) was calculated from the current data and plotted as a function of voltage. Normalized current (I/I
max
), elicited by test pulses at −10 
mV following 250 ms conditioning voltage pulses between −120 and −10 mV, was plotted as a function of the prepulse voltage. Data are 
fitted with Boltzmann functions (n ≥ 14). F. Typical whole-cell recordings from tumor cell in a tissue slice following depolarization to −10 
mV in control solution (i), following perfusion with 30 μM tetrodotoxin (TTX; ii), and washout (iii). G. Peak Na+ current density recorded 
from cells in the three indicated tumor regions (n = 20 in periphery, n = 12 in intermediate region, n = 7 in center). H. Peak Na+ current 
density of cells in tumor slices plotted vs. tumor volume. Pearson r = 0.11 (P = 0.49). I. Peak Na+ current density of cells in tumor slices 
plotted vs. number of days following implantation of tumor cells that recordings were made. Pearson r = 0.27 (P = 0.09). For (D) (E) and 
(G), data are mean ± SEM. For (H) and (I), solid line, linear regression; broken lines 95% confidence intervals.
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the tumor (>1 mm and ≤1.5 mm from the tumor surface, 
and >1.5 mm from the surface). We found that there was no 
significant difference in peak Na+ current density between 
cells across these regions (Figure 2G). Nor was there any 
difference in membrane voltage, membrane capacitance, 
or other Na+ current parameters (Table 1), suggesting that 
functional VGSC expression is broadly similar between 
tumor cells located in different regions of the tumor. 
Finally, there was no relationship between peak Na+ current 
density and tumor size, or stage at which the recordings 
were taken following orthotopic implantation of the tumor 
cells (Figure 2H, 2I). These findings demonstrate that Na+ 
current is retained on MDA-MB-231 cells in orthotopic 
tumors in vivo, and expression is broadly similar in cells 
in different tumor regions/sizes/stages. We postulated that 
Na
v
1.5 may be responsible for this Na+ current in tumor 
slices and may potentiate tumor progression in vivo, as it 
does in vitro. We next tested these possibilities.




In order to study the specific involvement of Na
v
1.5 
in tumor progression in vivo, we stably down-regulated its 
expression in MDA-MB-231 cells using lentiviral shRNA. 
We initially characterized four different shRNAs that each 
targeted both the neonatal and adult splice variants of Na
v
1.5, 
compared to a control non-targeting lentiviral shRNA. All 
four shRNAs reduced the mRNA level of both Na
v
1.5 
splice variants (Supplementary Figure S2A). ShRNA1 and 
shRNA2 were the most effective, and following selection 
of transduced clones, both shRNAs significantly reduced 
the mRNA level of both Na
v
1.5 splice variants by ~65–80% 
(P < 0.05; Supplementary Figure S2B). The β1 mRNA 
level was also lower in shRNA1-transduced cells, although 
this was not statistically significant (Supplementary Figure 
S2C). Both shRNA1 and shRNA2 significantly reduced the 
total cellular Na
v
1.5 protein level to a level sub-detectable 
by western blot (Figure 3A).
Whole-cell patch clamp recording revealed that both 
shRNA1 and shRNA2 significantly reduced Na+ currents 
compared to control shRNA-expressing cells (Figure 3B–
3D). However, shRNA1 was considerably more effective, 
reducing peak Na+ current density by 97% vs. 47% for 
shRNA2 (P < 0.001 and P < 0.05, respectively; Figure 3C, 
3D). Both shRNA1 and shRNA2 slightly but significantly 
reduced in vitro proliferation by ~10% (P < 0.05; 
Supplementary Figure S3A), although they had no effect on 
apoptosis measured by in vitro TUNEL assay (Supplementary 
Figure S3B). Both shRNA1 and shRNA2 moderately but 
significantly reduced cellular migration measured using an 
in vitro wound-healing assay by ~10% (P < 0.001 and P < 
0.01, respectively; Supplementary Figure S4A). Interestingly, 
shRNA1 significantly reduced in vitro invasion by 53% 
(P < 0.001; Supplementary Figure S3B), consistent with 
previous reports [13, 14, 17, 19], but shRNA2 had no effect 
(Supplementary Figure S4B). Together, these findings 
suggest that the relationship between Na
v
1.5 and cellular 
invasion may be both steep [17] and threshold-dependent, 
such that a minimum level of channel knock-down/inhibition 
(e.g. ≥ 60% [14, 17, 18]) is required to elicit an effect on 
invasion. Alternatively, lentiviral transduction of shRNA2 
may have led to the selection of cancer cells in which invasion 
is less dependent on Na
v
1.5. Given these possibilities, we 




1.5 down-regulation reduces tumor growth 
and local invasion in vivo
We next investigated the specific effect of Na
v
1.5 on 
tumor growth and invasion in vivo. Luciferase-expressing 
MDA-MB-231 cells stably expressing non-targeting control 
shRNA (“control cells”) or shRNA1 (“shRNA cells”) were 
orthotopically implanted into the inguinal mammary fat 
pads of female Rag2−/− Il2rg−/− mice and tumor growth 
was monitored by non-invasive bioluminescent imaging. 
Importantly, luciferase activity was very similar in 
both control and shRNA cells (Supplementary Figure 
S5A, S5B). Photon flux from shRNA tumors increased 
more slowly than for control tumors, reaching statistical 
significance after 4 weeks (P < 0.01; Figure 3E, 3F). 
Concurrent monitoring of tumor growth by caliper 
measurement revealed a similar relationship that became 
statistically significant after 2 weeks, thus confirming the 
bioluminescent data (P < 0.05; Figure 3G).
H&E staining revealed that both control and shRNA 
tumors were broadly similar, and contained some local 
invasion into surrounding tissue. Importantly, this invasion 
was noticeably reduced in shRNA tumors compared to 
control tumors (arrows, Figure 4A). The number of tumors 
displaying invasion into surrounding tissues, including 
fibroadipose tissue, muscle, mammary duct, and dermis, 
was significantly lower in shRNA than control tumors (P 
< 0.05; Figure 4B and Supplementary Figure S6A, S6B). 
The in vitro invasiveness of shRNA cells was not further 
reduced by TTX (30 μM), suggesting that the impaired 
invasion of these cells was specifically due to the absence 
of Na
v
1.5 activity (Figure 4C). Furthermore, the density 
of cells expressing matrix metalloproteinase-9 (MMP9), 
a marker correlating with invasive capacity in carcinomas 
[23, 32], was also significantly reduced by 61% in shRNA 
tumors compared to control tumors (P < 0.05; Figure 4D, 
4E). The MMP9 immunoreactivity was generally adjacent 
to human nuclear antigen (HNA)-positive cells, suggesting 
that it is being expressed by tumor cells, rather than by 
HNA-negative murine host stromal cells (Supplementary 
Figure S7). Thus, Na
v
1.5 promotes tumor growth and local 
invasion into surrounding tissue in vivo.
There was no difference in the density of Ki67+ 
dividing cells between control and shRNA tumors (Figure 
5A, 5B). Similarly, there was no difference in the density 
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of CD31-expressing vascular structures between control 
and shRNA tumors (Figure 5C, 5D). However, the density 
of activated caspase 3+ apoptotic cells was significantly 
increased by 2.7-fold in shRNA tumors compared to 
control (P < 0.01; Figure 5E, 5F). The shRNA had no 
effect on apoptosis in the same cells cultured in vitro 
(Supplementary Figure S3B), suggesting that Na
v
1.5/Na+ 
current may regulate apoptosis in vivo, but not in vitro. 
Interestingly, β1 over-expression also reduces the density 
of apoptotic cells in orthotopic tumors [22]. Thus, both 
Na
v




1.5 down-regulation inhibits metastasis
We have previously shown that phenytoin reduces 
metastasis of orthotopically implanted MDA-MB-231 
cells to the liver, lungs and spleen [23]. Similarly, Na
v
1.5 
inhibition by ranolazine has recently been shown to inhibit 
lung colonization by tail vein-injected MDA-MB-231 
cells in an experimental metastasis model [31]. Thus, 
pharmacological inhibition of Na
v
1.5 may be an effective 
tool to reduce metastatic dissemination. However, the 
specific effect of Na
v
1.5 on metastasis of orthotopically 
implanted tumors has not been investigated. Here, we 
monitored metastasis by bioluminescent imaging following 
post mortem resection of orthotopically implanted control 
and shRNA-expressing MDA-MB-231 cells (Figure 6A). 
We found that photon flux was significantly reduced in 
mice bearing shRNA tumors compared to mice bearing 
control tumors, and in the liver, lungs and spleen measured 
ex vivo (P < 0.001 for both; Figure 6B, 6C). We next 
studied metastasis to these organs at the cellular level in 
tissue sections. We detected isolated luciferase-expressing 
tumor cells in sections within all three organs, and also 
in much larger multicellular foci in the lungs Figure 6D, 
6F, 6H). Luciferase expression co-localized with HNA, 
which is absent in recipient mouse cells, thus confirming 
that luciferase expression was retained on the tumor cells at 
metastatic sites (Supplementary Figure S8). The density of 
luciferase-expressing tumor cells was significantly reduced 
in the liver, lungs and spleen of mice bearing shRNA tumors 
by ~60% compared to mice bearing control tumors (P < 
0.001; Figure 6E, 6G, 6I). Thus, Na
v
1.5 promotes metastasis 
to the liver, lungs and spleen in this orthotopic tumor model.
Na
v
1.5 down-regulation alters cellular morphology 
and reduces CD44 expression without affecting the 
epithelial-mesenchymal transition
β1 regulates protrusion of processes from the 
cell body of BCa cells via a trans-homophilic adhesion 
mechanism that requires fyn kinase and Na+ current, 
replicating its role in regulating neurite outgrowth in 
the CNS [22]. Similarly, Na+ current carried by Na
v
1.5 
promotes pro-invasive, elongate morphology in MDA-
MB-231 cells cultured on Matrigel [19, 31]. Thus, VGSC 
activity may represent a general mechanism by which BCa 
cells acquire an elongate, mesenchymal-like morphology. 
Here, we found that down-regulation of Na
v
1.5 expression 
with shRNA resulted in an increase in circularity of 
cultured MDA-MB-231 cells, i.e. a reduction in elongate 
morphology in favor of a more rounded epithelial-like 
phenotype (P < 0.001; Figure 7A, 7B). The reversion 
to a more epithelial-like morphology induced by Na
v
1.5 
down-regulation did not associate with any alteration 
in E-cadherin, N-cadherin, vimentin, slug or snail 
expression, suggesting that Na
v
1.5 does not regulate the 
expression of epithelial-mesenchymal transition (EMT) 
markers (Figure 7C–7G). However, the protein level of 
CD44, which promotes invasion and metastasis of BCa 
cells [33], was noticeably reduced in MDA-MB-231 cells 
expressing shRNA (P < 0.05 Figure 7H, 7I). Thus, Na
v
1.5 
may promote invasion and metastasis, at least in part, by 
inducing morphological changes via modulating CD44 
expression.
Table 1: Na+ current characteristics in tumor regions
Parameter Periphery Intermediate Center P
C
m
 (pF) 11.8 ± 0.6 11.4 ± 0.9 12.1 ± 1.1 0.87
V
m
 (mV) −7.6 ± 0.6 −8.8 ± 1.3 −7.2 ± 0.3 0.53
V
a
 (mV) −31.0 ± 1.8 −27.9 ± 3.1 −27.9 ± 0.4 0.55
V
p
 (mV) 9.8 ± 1.9 10.0 ± 3.4 9.3 ± 3.2 0.99
Activation V
1/2
 (mV) −27.3 ± 0.9 −26.9 ± 1.8 −26.2 ± 1.8 0.88
Activation k (mV) 7.1 ± 0.8 7.0 ± 1.5 5.7 ± 1.5 0.74
Inactivation V
1/2
 (mV) −85.6 ± 6.1 −90.0 ± 1.0 −89.1 ± 1.5 0.69
Inactivation k (mV) −13.0 ± 5.1 −4.5 ± 1.0 −5.9 ± 1.3 0.20
T
p
 at 0 mV (ms) 1.41 ± 0.11 1.51 ± 0.41 1.01 ± 0.11 0.56
Abbreviations: V
a
, activation voltage; V
p
 voltage at current peak; V
1/2
, half (in)activation voltage; k, slope factor; T
p
 time to 
peak. Periphery: ≤ 1 mm from tumor surface; intermediate zone: >1 mm and ≤ 1.5 mm from surface; centre: >1.5 mm from 
surface. Data are mean ± SEM.
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DISCUSSION
Increasing evidence suggests that VGSCs are 
expressed in cells from a range of types of cancer, 
including BCa [13, 14], cervical cancer [34, 35], 
colorectal cancer [21], lung cancer [25, 36], lymphoma 
[37], melanoma [38], mesothelioma [39], neuroblastoma 
[40], ovarian cancer [41] and prostate cancer [29]. VGSC 
β subunits have also been reported in BCa, non-small 
cell lung cancer and prostate cancer [22, 24, 25, 42, 43]. 
In BCa cells, the predominant α subunit, Na
v
1.5, is 
expressed mainly in its neonatal splice form [14]. A small 
study of patient tissue specimens revealed that the neonatal 
splice variant of Na
v
1.5 is up-regulated in BCa compared 
to non-cancer breast tissue [14]. Here, in a quantitative 
study using a larger patient cohort, we found that Na
v
1.5 
was significantly up-regulated in breast tumors compared 
with matched non-cancer breast tissue. The commercially 
available antibody used here recognizes both the adult and 
neonatal splice Na
v
1.5 variants, suggesting that although 
Figure 3: Effect of Na
v
1.5 on breast tumor growth in vivo. A. Western blot of Na
v
1.5 in MDA-MB-231 cells stably expressing 
control shRNA, or shRNA1, or shRNA2. Loading control = heat shock protein 90 (HSP90). B. Typical in vitro whole-cell recordings from 
MDA-MB-231 cells stably expressing control shRNA, or shRNA1, or shRNA2. Recordings were taken after depolarization to voltages 
in the range −80 to +30 mV in 5 mV steps following a 250 ms prepulse at −120 mV. C. Peak Na+ current density and D. current-
voltage relationship of MDA-MB-231 cells stably expressing control shRNA, or shRNA1, or shRNA2 (n = 8/each). E. Representative 
bioluminescent images of mice bearing tumors containing MDA-MB-231 cells stably expressing control shRNA (“Control”) and MDA-
MB-231 cells expressing shRNA1 (“shRNA”), 4 weeks after implantation. F. Bioluminescence measured from primary tumors on the 
indicated days post-implantation (n ≥ 13). G. Calculated volume derived from caliper measurement of primary tumors over the same period 
(n ≥ 13). Data are mean ± SEM; **P < 0.01; ***P < 0.001.
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the neonatal splice variant is predominant [14], splice 
variant specificity is not required to reliably evaluate 
Na
v
1.5 expression in tumors in vivo. Interestingly, this 
antibody has also been also used to demonstrate up-
regulation of Na
v
1.5 expression in colorectal tumor 
specimens [21]. At the mRNA level, SCN5A expression 
has been shown to correlate with metastasis, recurrence 
and reduced overall survival in BCa patients [14, 16]. 
However, there was no correlation between Na
v
1.5 protein 
expression and other histopathological characteristics in 
this cohort, although there was a moderate trend towards 
higher Na
v
1.5 expression in node-positive patients. In 
conclusion, our data add support to the notion that Na
v
1.5 
is up-regulated in BCa and suggest that further, larger 
scale studies are warranted to explore the relationship 
between Na
v
1.5 expression and other tumor parameters, 
including lymph node metastasis.
Na+ currents have been recorded from a number of 
metastatic cancer cell lines and cancer cells isolated from 
tumor biopsies in vitro using whole-cell patch clamp 
recording, suggesting that VGSCs may be functionally 
active in tumors [4, 34, 35]. In addition, pharmacological 
and siRNA studies have shown that Na
v
1.5 expression 
in metastatic MDA-MB-231 cells promotes several 
cellular behaviors associated with metastasis, including 
migration, galvanotaxis, detachment from substrates, 
and invasion [13, 14, 17, 44]. Similar results have been 
reported in cells from other tumor types, suggesting that 
contribution of VGSCs to migration/invasion of cancer 
cells may be a general phenomenon [4]. However, 
evidence supporting the specific involvement of Na
v
1.5 
in tumor progression in vivo is limited. Using tissue 
slice recording, we found that functional Na+ currents 
were retained in orthotopic tumors. Interestingly, the 
Na+ current density was broadly similar in cells at the 
tumor periphery compared to those deeper into the tumor 
slice, suggesting that Na
v
1.5 expression may be fairly 
uniform within tumors, rather than being up-regulated 
at the invasive edge. These data provide the first direct 
in vivo evidence confirming functional VGSC activity/
Na+ current in BCa cells tumors in situ, and suggest 
that Na
v
1.5 expression detected by IHC in patient 
Figure 4: Effect of Na
v
1.5 on local invasion from the primary tumor. A. Images of tissue sections from tumors containing 
MDA-MB-231 cells stably expressing control shRNA (“Control”) and MDA-MB-231 cells expressing shRNA1 (“shRNA”), stained with 
H&E showing (i) mammary fat pad and (ii) skeletal muscle invasion. Arrows, infiltration of tumor cells (T) into fibroadipose tissue (F) or 
skeletal muscle fibers (M) Scale bar, 100 μm. B. Number of animals in the experiment whose tumors displayed invasion at the indicated 
sites, detected by H&E staining (n = 7 for both control and shRNA). C. In vitro invasion of control and cells ± TTX (30 μM) for 24 h  
(n = 4; **P < 0.01; *P < 0.05; Neuman-Keuls test) D. Tumor sections stained with anti-MMP9 (red) and DAPI (blue). E. MMP9+ cells/
mm2 (n = 7). Data are mean and SEM.
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specimens may represent, at least in part, functional 
channels. Thus, we propose that Na
v
1.5 should be further 
investigated as a potential biomarker in BCa, and in vivo 
electrophysiological analysis may add value to traditional 
IHC/PCR approaches to studying biomarker expression.
We found that stable down-regulation of Na
v
1.5 
with shRNA reduced tumor growth in vivo. In addition, 
shRNA slightly reduced proliferation in vitro, although 
Ki67 expression was unchanged in vivo, suggesting that 
proliferation was not significantly altered in the tumors. 
In contrast, shRNA had no effect on apoptosis in vitro, but 
significantly increased density of apoptotic cells within the 
tumors. Interestingly, transient inhibition of Na
v
1.5 with 
TTX or phenytoin does not affect proliferation in vitro, 
although the effect on apoptosis has not been previously 
investigated [13, 14, 16]. Thus, the effect of Na
v
1.5 on 
proliferation and apoptosis appears to be both subtle 
and complex, and may be dependent on cellular context. 
For example, heterotypic interaction with, and support 
from the tumor microenvironment may be important for 
regulating Na
v
1.5-dependent tumor growth. Interestingly, 
we previously reported a similar situation for β1, 
which promotes tumor growth in vivo, but not in vitro, 
highlighting the importance of studying VGSC expression/
activity in situ [22].
Our data suggest that Na
v
1.5 promotes local invasion 
and metastatic dissemination to the liver, lungs and spleen 
in vivo. This finding broadly agrees with a recent study, 
using an experimental metastasis model, in which Na
v
1.5 
down-regulation reduced lung colonization of tail vein-
injected MDA-MB-231 cells [31]. Together, these findings 
suggest that Na
v
1.5 may promote both tumor growth and 
metastasis in BCa. The mechanism(s) by which VGSCs 
may promote tumor progression appear complex, and are 
reviewed in detail elsewhere [4, 45]. The prevailing model 
suggests that in MDA-MB-231 cells, Na+ current carried 
by Na
v
1.5 allosterically regulates NHE1 to increase H+ 
efflux, thus enhancing the activity of pH-dependent cysteine 
cathepsin proteases [18, 20]. In addition, Na
v
1.5 expression 
increases src tyrosine kinase activity and cortactin 
phosphorylation to enhance invadopodia formation and 
acquisition of an elongate invasive morphology [19]. 
Further complexity is added by the β1 subunit, which also 
promotes an invasive elongate cellular morphology, in part 
Figure 5: Effect of Na
v
1.5 on proliferation, apoptosis and angiogenesis. A. Tumor stained with anti-Ki67 (red) and DAPI 
(blue). B. Ki67+ nuclei/mm2 (n = 7). C. Blood vessels stained with anti-CD31 (red) and DAPI (blue). D. CD31+ blood vessels/mm2 (n = 7). 
E. Tumor stained with anti-activated caspase-3 (red) and DAPI (blue). F. Activated caspase-3+ cells/mm2 (n = 7). Data are mean and SEM; 
**P < 0.01. Scale bar, 100 μm.
Oncotarget32923www.impactjournals.com/oncotarget
via a trans-homophilic adhesion interaction that requires fyn 
kinase [22]. Interestingly, β1-mediated process outgrowth 
also requires Na+ current, suggesting that Na
v
1.5 and β1 
may function co-operatively in promoting invasion and 
metastasis. Our data here add to this model by suggesting 
that Na
v
1.5 expression does not enhance invasive elongate 
cellular morphology by altering the EMT, but may directly/
indirectly influence expression of the metastasis-promoting 
CAM, CD44 (Figure 8) [33, 46]. Adhesion of CD44 to its 
ligand hyaluronan results in src activation and cortactin 
phosphorylation [47–49]. Thus, Na
v
1.5 may either directly/
indirectly regulate this signaling cascade, or regulate 
cortactin phosphorylation through a parallel pathway.
In conclusion, our data suggest that Na
v
1.5 is up-
regulated in BCa and promotes both tumor growth and 
metastasis. Thus, VGSC α and β subunits may be general 
mediators of an invasive phenotype in tumor cells. Given that 
pharmacological targeting of VGSCs inhibits tumor growth 
and metastasis in vivo [23, 30, 31], these findings suggest 
that Na
v
1.5 expression and/or Na+ current may be a useful 
biomarker for cancer progression, and VGSC inhibition may 
be a novel therapeutic strategy to reduce metastasis.
Figure 6: Effect of Na
v
1.5 on breast cancer metastasis. A. Bioluminescent images of metastases in mice bearing tumors 
containing MDA-MB-231 cells stably expressing control shRNA (“Control”) and MDA-MB-231 cells expressing shRNA1 (“shRNA”). 
B. Bioluminescence measured from the indicated anatomical sites (n ≥ 12). C. Bioluminescence measured ex vivo from the liver, lungs 
and spleen (n ≥ 12). Liver D. lungs F. and spleen H. stained with anti-luciferase (red) and DAPI (blue). E, G, I. luciferase+ cells/mm2 at 
each site (n ≥ 20). Data are mean and SEM; ***P < 0.001. For (B) and (C), P < 0.001 between control and shRNA (two-way ANOVA). 




Investigation has been conducted in accordance 
with the ethical standards according to the Declaration 
of Helsinki and according to national and international 
guidelines and has been approved by the University of 
York Ethical Review Process.
Cell culture
Generation of MDA-MB-231 cells stably expressing 
eGFP and firefly luciferase was described previously [22]. 
MCF-7 cells were a gift from M. Djamgoz, Imperial 
College London. BT474 and SKBR3 cells were a gift from 
J. Rae, University of Michigan. MCF-10A cells were a gift 
from N. Maitland, University of York. HEK293 cells stably 
expressing Na
v
1.5 were a gift from L. Isom, University of 
Michigan. Cell lines were grown in Dulbecco’s modified 
eagle medium (DMEM) supplemented with 5% FBS 
and 4 mM L-glutamine. Molecular identity of cells was 
confirmed by short tandem repeat analysis. Cells were 
confirmed as mycoplasma-free using the DAPI method.
Pharmacology and in vitro assays
TTX was diluted in culture medium to 30 μM. 
Staurosporine was prepared as stock in DMSO and 
then diluted in culture medium. In assays that exceeded 
24 h, treatments were replaced daily. In vitro migration 
and invasion were determined using wound healing and 
Figure 7: Na
v
1.5 regulates CD44, but not EMT marker expression. A. Images of MDA-MB-231 cells stably expressing control 
shRNA (“Control”) and MDA-MB-231 cells expressing shRNA1 (“shRNA”), stained with anti-CD44 (red). Scale bar, 20 μm. B. Circularity 
index of control and shRNA cells (n ≥ 34). C. Western blot of E-cadherin in control and shRNA cells. Positive control = MCF-7 cells. D. Western 
blot of N-cadherin in control and shRNA cells. Positive control = rat brain. E. Western blot of vimentin in control and shRNA cells. F. Western blot 
of slug in control and shRNA cells. G. Western blot of snail in control and shRNA cells. H. Western blot of CD44 in in control and shRNA cells. 
I. CD44 protein levels determined by densitometry (n = 5). Loading control for densitometry, α-tubulin. Data are mean and SEM; ***P < 0.001.
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Matrigel assays [16]. Apoptosis was determined using 
DeadEnd fluorometric TUNEL assay (Promega). Cell 
viability and proliferation were determined using trypan 
blue and MTT assays [16].
RNA interference, RNA isolation and PCR
MDA-MB-231 cells stably expressing eGFP and 
luciferase were stably transduced with recombinant 
lentivirus for one of four different shRNAs targeting 
Na
v
1.5 or a non-targeting control shRNA, according to 
the manufacturer’s instructions (MISSION pLKO.1-puro 
shRNA transduction particles; Sigma). Sequences are in 
Supplementary Table S2. ShRNA-expressing cells were 
selected using resistance to puromycin and individual 
colonies were expanded for screening by qPCR. RNA 
extraction, cDNA synthesis and qPCR were performed as 
described previously [22]. Relative gene expression was 
quantitated using the comparative C
T
 method [50]. Primers 
are in Supplementary Table S3.
Patient tissue samples
The study cohort contained tissue samples from 
66 BCa cases obtained from the Breast Cancer Now 
Tissue Bank under tissue request number TR000032. 
BCa and matched non-cancer breast tissue was available 
for 36 cases. Patients provided consent to the Breast 
Figure 8: A model for Na
v
1.5 involvement in tumor progression. Na+ influx carried by Na
v
1.5 allosterically regulates NHE1 
to increase H+ efflux, lowering extracellular pH and enhancing cathepsin protease activity [18, 20]. Na
v
1.5 also increases src activity and 
cortactin phosphorylation, resulting in cytoskeletal changes, invadopodia formation and acquisition of an elongate invasive morphology 
[19]. The β1 subunit enhances process outgrowth via a trans-homophilic adhesion mechanism that requires fyn kinase and Na+ current 
[22]. Na
v
1.5 positively regulates CD44 protein expression, which may in turn enhance CD44-mediated src activation and increase cortactin 
expression/activity [47–49]. Na
v
1.5 expression is maintained by a positive feedback mechanism via protein kinase A (PKA) [26, 57]. 
Additional potential partners in this signaling network have been omitted for clarity, and are reviewed in detail elsewhere [4, 45]. Figure 
was produced using ScienceSlides software.
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Cancer Now Tissue Bank for their tissues to be used 
for research. Dataset and sample characteristics were 
described previously [22]. Immunohistochemistry was 
performed using the EnVision+ System-HRP kit (Dako) 
and anti-Na
v
1.5 antibody (1:100; Alomone) [21, 22]. 
Antibody specificity was confirmed by preadsorption to 
immunizing peptide (4:1 ratio peptide:antibody; Alomone) 
for 1 h prior to application. Rat heart tissue (Abcam) 
was used as a positive control for Na
v
1.5 staining in 
a separate experiment (Supplementary Figure S1). β1 
immunohistochemistry was performed previously [22]. 
Slides were scanned at 40X using an Aperio ScanScope. 
Na
v
1.5 immunoreactivity in the tumor samples was scored 
independently by two investigators (WJB and RMS, a 
breast histopathologist) using the Allred method [22, 
51]. The proportion of Na
v
1.5-expressing cells in a given 
section was given a score (none: 0; < 1/100: 1; 1/100 to 
1/10: 2; 1/10 to 1/3: 3; 1/3 to 2/3: 4; >2/3: 5), followed 
by an estimate of staining intensity (none: 0; weak: 1; 
intermediate: 2; strong: 3), and then the proportion and 
intensity scores were summed to give an overall score of 
0–8. A score ≤ 5 was considered “low” and > 5 was “high.” 
Scoring was performed blinded to outcome data.
Western blotting
SDS-PAGE was performed as described [22]. The 
following antibodies were used: rabbit anti-Na
v
1.5 (1:1000; 
Cell Signaling Technology); rabbit anti-E-cadherin (1:1000; 
Cell Signaling Technology); rabbit anti-N-cadherin (1:1000; 
Cell Signaling Technology); rabbit anti-vimentin (1:1000; 
Cell Signaling Technology); rabbit anti-Slug (1:1000; Cell 
Signaling Technology); rabbit anti-Snail (1:1000; Cell 
Signaling Technology); mouse anti-CD44 (1:1000; AbD 
Serotec); rabbit anti-heat shock protein 90 (HSP90; 1:1000; 
Cell Signaling Technology), and mouse anti-α-tubulin 
(1:10,000; Sigma).
Orthotopic breast tumor model
All animal procedures were performed after approval 
by the University of York Animal Welfare and Ethical 
Review Body and under authority of a UK Home Office 
Project License. Six week-old female Rag2−/− Il2rg−/− mice 
were obtained from the Yorkshire Cancer Research Unit, 
University of York, (3–5 per specific pathogen free cage). 
1 × 106 MDA-MB-231 cells suspended in Matrigel (20% 
v/v in saline) were injected into the left inguinal mammary 
fat pad of each animal whilst under isoflurane anesthesia. 
For tumor growth and metastasis assays, a total of 29 mice 
were used across 7 independent replicated experiments. 
Tumor growth was monitored weekly by bioluminescence 
imaging [22]. Animal weight and the length and width 
of each tumor (in mm) were measured every 2–4 days. 
Tumor volume was calculated as 0.5 × (length × width2). 
Mice were euthanized 4 weeks following implantation of 
tumor cells and metastatic bioluminescence was measured 
[22]. Tumors and organ sites of metastasis were fixed in 
4% paraformaldehyde and frozen [52].
Tumor slice preparation for electrophysiology
For electrophysiological slice recording, a total of 18 
animals were used across 6 independent cages. Following 
euthanasia (20–37 days following implantation of cancer 
cells), tumors were dissected and quickly placed into 
ice-cold physiological saline solution (PSS) containing 





D-glucose and 5 HEPES, (pH 7.2). The tumor was cut to 
~5 × 5 mm with a razor and fixed with cyanoacrylate glue 
onto the pre-chilled pedestal of an oscillating tissue slicer 
(Campden Instruments). The tissue block was immersed in 
ice-cold PSS and sliced at 250 μm. Slices were maintained 
in a homemade tissue holding chamber containing PSS for 
> 20 min at room temperature (21°C) prior to recording. 
In all cases, recordings were taken from cells in (1) the 
periphery (≤1 mm from tumor surface, (2) the intermediate 
zone (>1 mm and ≤ 1.5 mm from surface), and (3) the 
center (>1.5 mm from surface).
Electrophysiology
The whole-cell patch clamp technique was used 
to record plasma membrane Na+ currents, from cells in 
slices, or cells grown on glass coverslips [16, 24]. The 
extracellular recording solution contained (in mM): 144 




, 5.6 D-glucose and 5 
HEPES (pH 7.2), and the intracellular recording solution 





10 HEPES, 11 EGTA, (pH 7.4) [26]. Voltage clamp 
recordings were made using a Multiclamp 700B amplifier 
(Molecular Devices) compensating for series resistance 
by 40–60%. Currents were digitized using a Digidata 
1440A interface (Molecular Devices), low-pass filtered at 
10 kHz, sampled at 50 kHz and analyzed using pCLAMP 
10.4 software (Molecular Devices). Leak current was 
subtracted using a P/6 protocol [53].
Immunohistochemistry and immunocytochemistry
H&E staining was performed as described [22]. 
The following primary antibodies were used for IHC and 
immunocytochemistry (ICC) [22]: rabbit anti-MMP9 
(1:5000; Abcam); rabbit anti-Ki67 (1:5000; Abcam); 
rabbit anti-activated caspase-3 (1:200; R&D Systems); 
rabbit anti-CD31 (Santa Cruz Biotechnology); mouse 
anti-CD44 (1:100; AbD Serotec); mouse anti-HNA 
(1:100; Millipore). Secondary antibodies were Alexa-568-
conjugated goat anti mouse/rabbit, unless stated otherwise 
(1:500; Invitrogen). Tyramide signal amplification was 
used for MMP9 [54]. Samples were mounted in Prolong 
Gold with DAPI (Invitrogen). H&E and fluorescent-
stained tissue sections were scanned independently 
at 20X using a Zeiss AxioScan.Z1 slide scanner. 
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Stained cultured cells were viewed on a Zeiss Axio 
Observer.Z1 microscope with LSM 710 confocal 
laser scanner. Images were exported into ImageJ for 
processing. Brightness/contrast was adjusted using the 
ImageJ “Auto” function. Density of MMP9+, Ki67+ 
or activated caspase-3+ cells, tumor vascularity and 
metastasis to liver/lungs/spleen were measured across 
scanned images of whole sections (3 sections per animal), 
blinded to treatment [22]. For ICC, confocal Z-series 
projections were flattened using the maximum signal 
and circularity ([4π.Area]/[Perimeter2]) was computed 
for individual cells using ImageJ. For a perfect circle, 
circularity = 1, and for an increasingly elongated shape, 
circularity approaches 0 [55].
Data analysis
Data are mean and SEM unless stated otherwise. 
Statistical analysis was performed using GraphPad Prism 
6f. Pairwise statistical significance was determined with 
t-tests. Multiple comparisons were made using ANOVA 
and Tukey post-hoc tests, unless stated otherwise. TUNEL 
assay and tumor local invasion data were analyzed by 
two-way ANOVA. Metastatic bioluminescence data were 
log-transformed and analyzed by two-way ANOVA. 
Correlation was determined using Pearson’s r test. 
Association between Na
v
1.5 expression and histoclinical 
data was determined using Fisher’s exact or χ2 tests. 
Results were considered significant at P < 0.05.
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